A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of nemonoxacin in healthy Chinese volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: TaiGen Biotechnology Co., Ltd.

Criteria

Inclusion Criteria:

1. Healthy male or female, aged 18 ~45

2. A male volunteer should be willing to use a double-barrier contraception until the study is completed, and should not make his partner pregnant during the study and within 3 months after completing the study

3. Volunteers who have never used any tobacco or nicotine-containing product within three months before use of the investigational product

4. Volunteers who are willing to abstain from caffeine- or xanthine- containing drinks or food within 24h before being enrolled in the study and throughout the study,such as coffee and tea,chocolate,alcohol, grapefruit juice,orange juice,etc.

5. The body mass index (BMI) of the volunteer must be 19~24, and the weight of a male should be at least 50kg,and that of a female should be at least 45kg.

6. Volunteers who are able to sign the informed consent form (ICF) of their own accord.

Exclusion Criteria:

1. History of diabetes,or cardiovascular,hepatic or renal disease.

2. Had surgery or trauma within 6 months prior to this study

3. Alcohol or drug abuse

4. HIV, HBV or HCV positive

5. subject used any known hepatic enzyme inducer/hepatic enzyme inhibitor product within 30 days prior to the study

6. Used any prescribed drug (including traditional chinese medicine) within 14 days prior to the study

7. Donated 400ml of blood or plasma within 3 months prior to this study

8. Have an abnormal laboratory examination value that exceeds the normal range by 10%

9. Drug allergies

10. Have cardiac disorders or have a family history of cardiac disorders

11. Have abnormal 12-lead ECG during screening

12. Pregnant or lactating

13. Participated in any study within 3 months prior to this study

14. according to the investigator's judgment, affect the safety or efficacy evaluation.